N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Daniel Duprez, Jacqueline Neuhaus, Russell Tracy, Lewis Kuller, Steven Deeks, Chloe Orkin, Albrecht Stoehr, Ian Woolley, James Neaton

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression.
Original languageEnglish
Pages (from-to)651 - 657
Number of pages7
Issue number5
Publication statusPublished - 2011

Cite this